Diagnostic Center | March 12, 2024
Pfizer announces positive Phase 3 trial of ADCETRIS regimen in patients with DLBCL
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
The product combines proven efficacy of Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg in an Extended Release formulation
ANVISA issues CGMP to Concord Biotech’s Unit I
Sadhana Nitro Chem's plant is the second plant in the world to manufacture pAP from Nitrobenzene
Acquisition of exclusive commercialization rights for European markets
Cipla completes transfer of Generics Business Undertaking
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Eugia Pharma Specialities restarts production at terminally sterilized product lines
Subscribe To Our Newsletter & Stay Updated
